The National Prostate Cancer Audit (NPCA) has published a short report on the use of the Cambridge-developed Cambridge Prognostic Groups for non-metastatic prostate cancer and its utility and benefit in better reporting of treatment trends and patterns in the UK. This follows on from a paper jointly published last year.
The NPCA will be used to classify men’s prostate cancer risk in future National Prostate Cancer Audit reporting, replacing the current three-tiered system of low-, intermediate- and high-risk groups.
“From the audit’s perspective, using the CPG allows for classification using more granular information which also adds more men to the lowest risk category. This makes the audit indicator more able to identify real variation between providers so that the potential ‘over-treatment’ of patients can be appropriately
addressed”
